Kornimate/medical-research-clean huggingface dataset:
effect of lateral positions on the shape of upper airway

Conditions: Airway Remodeling; Radiography in Otolaryngology; Position; Patency; Morphology

Summary: the severity and frequency of respiratory events is increased in the supine body posture compared with the lateral position in emergency, difficult airway patients. the mechanism responsible is not clear but may relate to the effect of position on upper airway shape and size. 3d finite element model of upper airway filling based on mri image reconstruction can effectively reflect the anatomy of the upper airway. this study compared the effect of body position on upper airway shape and size in individuals with lateral position among sedated subjects.

anesthesiologists may encounter situations in which a accidental loss of airway patency occurs in patients in a lateral patient position during surgery. intubation is required in the lateral position in cases of oropharyngeal bleeding to reduce the risk of aspiration, or in airway management in some patients with limited posture. the severity and frequency of respiratory events is increased in the supine body posture compared with the lateral position in emergency, difficult airway patients. the mechanism responsible is not clear but may relate to the effect of position on upper airway shape and size secondary to gravitational effects. lateral positioning decreases upper airway obstruction in sleeping individuals, children breathing spontaneously, and adults during general anesthesia. the mechanical upper airway properties may become the dominant factor governing upper airway collapsibility during sedation due to the significant depression of consciousness and the impairment of neural mechanisms controlling compensatory neuromuscular responses. anesthesiologists and surgeons who are responsible for airway management during procedures under sedation and the perioperative period should be well versed with the physiological and pathophysiological mechanisms affecting upper airway patency. 3d finite element model of upper airway filling based on mri image reconstruction can effectively reflect the anatomy of the upper airway. the primary aim of this study was to determine the changes in upper airway shape and size that occur when sedated, spontaneously breathing adults are placed in the lateral position. these findings may provide new guidance for the evaluation and prediction of difficult airway during clinical anesthesia.

Eligibility criteria:
inclusion criteria: 1. subjects aged over than 18 years and less than 100 years 2. the american society of anesthesiologists (asa) score was grade i to ii 3. there was no serious cardiopulmonary disease exclusion criteria: 1. unable to maintain oxygenation before or during the examination and requiring intervention 2. those with preoperative arrhythmia requiring intervention 3. thosewith severe hematological diseases, severe metabolic diseases, severe liver and kidney organ insufficiency 4. those do not consent to participate in the study
ft516 in subjects with advanced hematologic malignancies

Conditions: Acute Myelogenous Leukemia; B-cell Lymphoma

Summary: this is a phase 1/1b dose-finding study of ft516 as monotherapy in acute myeloid leukemia (aml) and in combination with cd20 directed monoclonal antibodies in b-cell lymphoma. the study includes three stages: dose escalation, safety confirmation, and dose expansion.


Eligibility criteria:
key inclusion criteria: diagnosis of the following: regimen a (ft516 monotherapy): * primary refractory aml * relapsed aml defined as not in cr after 1 or more re-induction attempts; if \>60 years of age, prior re-induction therapy is not required regimen b (ft516 + rituximab or obinutuzumab): * histologically documented b-cell lymphoma expected to express cd20 who have relapsed after or failed to respond to at least on prior treatment regimen and for whom there is no available therapy expected to improve survival. all subjects: * provision of signed and dated informed consent form (icf) * age ≥18 years old * stated willingness to comply with study procedures and duration * presence of measurable disease key exclusion criteria: all subjects: * females of reproductive potential who are pregnant or lactating, and males or females not willing to use a highly effective form of contraception from screening through the end of the study * eastern cooperative oncology group (ecog) performance status ≥2 * evidence of insufficient organ function * receipt of therapy within 2 weeks prior to cycle 1 day 1 or within five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to cycle 1 day 1 * currently receiving or likely to require systemic immunosuppressive therapy * prior allogeneic hsct or allogeneic car-t within 6 months of cycle 1 day 1, or ongoing requirement for systemic graft-versus-host therapy * receipt of an allograft organ transplant * known active central nervous system (cns) involvement by malignancy. * clinically significant cardiovascular disease * clinically significant infections including: known hiv infection; known active hepatitis b (hbv) or hepatitis c (hcv) infection * live vaccine \<6 weeks prior to start of lympho-conditioning * known allergy to human albumin and dmso additional exclusion criteria for ft516 monotherapy regimen: diagnosis of promyelocytic leukemia with t(15:17) translocation additional exclusion criteria for ft516 plus monoclonal antibody regimens: diagnosis of waldenstrom macroglobulinemia

Keywords: aml lymphoma
efficacy of postoperative pain control between transarticular vs periartiucular multimodal drug infiltration in total hip arthroplasty: double-blinded randomized control trial

Conditions: Pain, Post Operative; Arthroplasty Complications

Summary: this research aim to improve postoperative outcome in total hip arthroplasty(tha) by using local mixture infiltration as bupivacaine + nsaid + epinephrine + tranxemic acid. in the present time these mixture components has shown to improve tha outcome by aspect of postoperative pain control, postoperative opioid consumption, postoperative bleeding, los and postoperative rehabilitation without increasing complication but the accuracy of infiltration technique which gives the best outcome has not been yet discovered.recently study by hashimoto et al has risen that these technique can be administrated by both periarticular and intra-articular approach.by considering the complexity of human anatomy around the hip tissue we assume that the intra-articular(transarticular) may given equivalence (may be better) outcome with lowering procedural related complication comparing to periarticular infiltration approach.


Eligibility criteria:
inclusion criteria: * patient who would go on cemented and cementless tha * age 45-60 years of age * voluntary decision exclusion criteria * bilateral tha * revision surgery * history of pelvic and hip surgery previously * allergy to medication in protocol * ckd stage 4-5, chronic liver disease with child pugh b or c * pregnancy * history of hip injection * u/d * hypercoagulable state * abnormal laboratory coagulation study as inr \> 1.4 or aptt \> 1.4 * abnormal platelet function * thrombocytopenia * pe , dvt, ischemic stroke, cad/ischemic heart disease * use of anticoagulant or hormonal usage * anesthesia by general anesthesia or additional nerve block * can not understand pca usage * use postopertive wound drainage

Keywords: total hip arthroplasty transarticular multimodal drug infiltration periarticular multimodal drug infiltration
comparison to psychological, medical and emotional influencing communication and achievement factors to oncogenetics tests

Conditions: Cancer; Colorectal Cancer; Breast Cancer; Ovarian Cancer

Summary: the purpose of the study was to analyze the psychological and emotional determinants of domestic dissemination of information about genetic risk of cancer and to compare the level of diffusion syndromes in breast/ ovarian cancer ( brca1 / brca2) and colon/endometrial ( hnpcc )

the risk associated with a genetic predisposition is among the various forms of risk, the strongest identifiable risk . it enables to offer people at risk an appropriate medical care (screening, prevention ) the clinical benefit is validated today. the person with whom a predisposing mutation has been identified must communicated its related information on the risk of cancer and the ability to perform genetic analysis. it appears that this dissemination of information is not always optimal, as shown in figures from the national cancer institute joined the project; the purpose of the study was to analyze the psychological and emotional determinants of domestic dissemination of information about genetic risk of cancer and to compare the level of diffusion syndromes in breast/ ovarian cancer ( brca1 / brca2) and colon/endometrial ( hnpcc )

Eligibility criteria:
inclusion criteria: * patient having a deleterious genetic mutation on genes brca1 and/or brca2 and or on genes mmr * the patient being of the family (who carried out a full analysis of brca1/brca2 and/or those mmr ) exclusion criteria: * patient not carrying a deleterious genetic mutation on the brca1/2 genes and/or those of the mmr system, * patient under guardianship, curator or unable to give his non-opposition, * adult patients protected by law.

Keywords: genetic testing genes brca1 genes brca2 mutation family disclosure psychology dna mismatch repair genetic predisposition to disease cancer oncology
imiquimod in children with plaque morphea

Conditions: Scleroderma, Localized

Summary: morphea is very hard to treat. in a small number of adult patients, imiquimod has proven to be beneficial in decreasing the thickness of the morphea plaques , while improving their appearance. there are no studies to date proving its safety and efficacy in children with this disease. we propose to conduct a pilot study to assess to potential efficacy and relative safety of imiquimod in children with plaque morphea.

design: prospective, open label, pilot study settings: the hospital for sick children, specialized morphea clinic study population: * children 6-18 years of age * plaque morphea measuring less than 10 cm2 in diameter ( for children with multiple lesions, only one will be treated) intervention: topical imiquimod applied 3-5 times a week for 6 months outcome measures: decrease in the thickness of the skin by clinical scores and ultrasonography duration of the study: 12 months ( 2 baseline visits, 1 intervention visit, 5 follow-up visits)

Eligibility criteria:
inclusion criteria: * age at diagnosis 6 to 18 years of age * morphea plaques * female subjects of childbearing potential must have a negative urine pregnancy test * signed consent/assent form exclusion criteria: * children who received topical corticosteroids, tacrolimus, vitamin d derivatives (calcipotriol, calcipotriol-betamethasone dipropionate) to the affected area in the previous four weeks * children who were previously treated with imiquimod on the affected areas * children with no demonstrable ultrasonographic changes at the baseline evaluation * children with evidence of skin breakdown on the proposed area to be treated at the time of enrollment due to potential increased absorption of the medication through impaired skin barrier * female subjects of childbearing potential who do not agree to practice effective birth control methods for the duration of the study * children who are/were (in the past 6 months) treated with systemic medications such as methotrexate and/or systemic corticosteroids * co-morbidities: systemic sclerosis, juvenile rheumatoid arthritis, other systemic diseases

Keywords: localized scleroderma morphea imiquimod pediatrics
photodynamic therapy with hpph in treating patients with non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. photosensitizing drugs such as hpph are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. purpose: phase i trial to study the effectiveness of photodynamic therapy with hpph in treating patients who have non-small cell lung cancer.

objectives: * determine the systemic and normal tissue toxicity of photodynamic therapy with hpph in patients with early stage or centrally obstructing non-small cell lung cancer. * determine, preliminarily, the efficacy of this regimen in these patients. outline: this is a dose-escalation study of hpph. patients receive hpph iv over 1 hour on day 1. patients undergo laser light therapy via bronchoscopy on day 3. cohorts of 3-6 patients receive escalating doses of hpph until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. patients are followed for at least 6 months. projected accrual: approximately 15-17 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologically confirmed microinvasive or centrally obstructing non-small cell lung cancer * squamous cell carcinoma * adenocarcinoma * large cell carcinoma patient characteristics: age: * 18 and over performance status: * karnofsky 50-100% or * ecog 0-2 life expectancy: * not specified hematopoietic: * wbc at least 2,000/mm\^3 * platelet count at least 50,000/mm\^3 hepatic: * bilirubin no greater than 3.0 mg/dl * alkaline phosphatase no greater than 3 times upper limit of normal (uln) * sgot no greater than 3 times uln * pt no greater than 1.5 times uln renal: * creatinine no greater than 3.0 mg/dl pulmonary: * no severe chronic obstructive pulmonary disease that would preclude study other: * not pregnant * fertile patients must use effective contraception * no contraindications to bronchoscopy * no porphyria * no hypersensitivity to porphyrin or porphyrin-like compounds prior concurrent therapy: biologic therapy: * prior biologic therapy for lung cancer allowed chemotherapy: * at least 4 weeks since prior chemotherapy * no concurrent chemotherapy endocrine therapy: * prior endocrine therapy for lung cancer allowed radiotherapy: * at least 4 weeks since prior radiotherapy * no concurrent external beam radiotherapy surgery: * no concurrent surgery other: * prior therapy for lung cancer allowed

Keywords: squamous cell lung cancer large cell lung cancer adenocarcinoma of the lung stage i non-small cell lung cancer stage ii non-small cell lung cancer
dose-modified emapalumab and ruxolitinib (e-ru) regimens for hemophagocytic lymphohistiocytosis

Conditions: Hemophagocytic Lymphohistiocytosis (HLH)

Summary: this study is trying to evaluate the efficacy and safety of dose-modified emapalumab and ruxolitinib (e-ru) regimens for the treatment of active hemophagocytic lymphohistiocytosis.

this clinical trial is designed to evaluate a new treatment strategy for patients with active hemophagocytic lymphohistiocytosis (hlh)-a rare but severe immune disorder characterized by excessive inflammation and immune system activation. hlh can be life-threatening if not treated effectively. the study is prospective and multicenter, meaning it will be conducted at multiple hospitals and medical institutions, and patients will be followed over time to assess treatment outcomes. we aim to test the combination of two medications: 1. emapalumab, a monoclonal antibody that blocks interferon-gamma, a key driver of the overactive immune response seen in hlh. in this trial, it will be used at a lower-than-standard dose to reduce potential side effects. 2. ruxolitinib, a jak1/2 inhibitor that can reduce inflammation by interfering with immune signaling pathways. it will be administered at a higher-than-standard dose to enhance its therapeutic effects.

Eligibility criteria:
inclusion criteria: 1. fulfillment of at least five of the eight hlh-2004 criteria for hlh; 2. age 1-70 years old; 3. no prior chemotherapy for hlh; 4. confirmed not pregnant and willing to use effective contraceptive measures during the study period, with the last dose of medication administered at least 12 months prior; 5. signed informed consent prior to study participation. exclusion criteria: 1. according to the new york heart association (nyha) score, patients with heart disease of grade ii or above (including grade ii); 2. hiv-infected patients; 3. patients with severe renal dysfunction (glomerular filtration rate \<15 ml/min); 4. patients with severe liver cirrhosis (meld score\>20); 5. uncontrollable infections (including lung infections, intestinal infections, etc.); 6. have serious mental illness; 7. have a history of active tumor; 8. participate in other clinical investigators at the same time; 9. people with central nervous system involvement; 10. exclusion criteria related to concomitant medication.
the histological analysis in renal transplantation patients with deterioration of graft function

Conditions: Chronic Allograft Dysfunction

Summary: identify the cause of chronic allograft dysfunction using a combination of comprehensive clinical and histologic information in chinese renal transplant recipients, then to identify the position of cni nephrotoxicity in cad.chronic allograft dysfunction reflects the dual impact of both immunologic and nonimmunologic (primarily calcineurin inhibitor \[cni\]nephrotoxicity) injury. in previous, cni nephrotoxicity is overstated and considered one of the major causes of cad, however, recently there has been found most death-censored graft losses to be the result of alloimmune or autoimmune injury, with only a minority of cases attributable to cni toxicity. unfortunately, situation of objective cni toxicity in cad in china is not well analyzed. to improve perception of neo safety with more local evidence, we want to do a retrospective study to identify the cause of chronic allograft dysfunction using a combination of comprehensive clinical and histologic information in chinese renal transplantation recipients.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * kidney transplant recipients, only including recipients of living-donor grafts * underwent an allograft biopsy between january 2005 and december 2011 because of developing deterioration of graft function\*. * deterioration of function was defined as (1) an unexplained and persistent greater than or equal to 25% increase of cr over baseline (in the absence of potential confounding factors) or (2) new onset proteinuria (defined as albumin/cr ratio ≥0.2 or a protein/cr ratio \>0.5). exclusion criteria: * multiple organ transplants, prior transplant with any other organ or tissue * patients who did not have the information regarding the pathological diagnosis * patients who did not have the histological sections of the allograft biopsy
nuclear factor kappa-b (nfkb1) polymorphism and organ injury after cardiac surgery

Conditions: Single Nucleotide Polymorphism; Acute Lung Injury; Kidney Injury

Summary: nfkb1 -94ins/del polymorphism has been reported to be associated with reduced promoter activity of nfkb1 and several clinical diseases, but the clinical results cannot always be replicated. besides, mutate allele is associated with alleviated inflammation in ulcerative colitis and some tumors, but aggravated inflammation in ards. the clinical value of this polymorphism remains controversial. this study was performed to investigate the association of nfkb1 -94ins/delattg polymorphism with lung and/or kidney injury after cardiac surgery with cpb.


Eligibility criteria:
inclusion criteria: * chinese han unrelated population * undergoing elective cardiac surgery with cpb exclusion criteria: * malignant tumor * autoimmune disease, immunodeficiency or immunosuppressive therapy * chronic renal disease (glomerular filtration rate \ a) * copd, tuberculosis or other chronic pulmonary diseases * anemia with hemoglobin lower than 90mmhg * bleeding disorders * postoperative pericardial tamponade requiring re-operation * postoperative low cardiac output syndrome or acute pulmonary edema after left cardiac failure.
impact of a novel heart failure medication decision aid

Conditions: Heart Failure

Summary: a modified zelen design randomised controlled trial over 6 months period is designed to investigate the influence of a heart failure medication decision aid prior to clinic session on shared decision making and its long term effect. participants are randomised to either the decision aid arm or the usual care arm.

a novel heart failure (hf) medication decision aid (da) has been constructed, taking into account the needs of both patients and clinicians. developed with a focus on brevity, this single-page da is designed to offer patients a quick and concise overview of the information they desire about their medication ahead of their clinic session. it encompasses personalised cost information, considering the subsidies available in singapore. the aim of the da is to improve the communication between clinicians and hf patients. the conduct of this randomized controlled trial (rct) is to study the effectiveness of the hf da in the real-world setting. patients are randomized to either the da arm or the usual care (uc) arm. in the da group, patients will be provided with a da featuring duration and frequency of use, benefits, side effect and cost information about angiotensin receptor neprilysin inhibitor and angiotensin-converting enzyme inhibitor medications. these patients will then be tasked to choose a preferred medication and reflect on which attribute holds the most significance for them. the preferred medication will be communicated to the clinicians during the clinic session. for the uc arm, clinicians will manage the encounter as per current usual routine.

Eligibility criteria:
inclusion criteria: * diagnosed with heart failure with reduced ejection fraction (hfref) * singaporean nationality exclusion criteria: * patient is currently on medifund or have medical claims pro-ration system (mcps) * pregnant * age 21 years and below * incapable of personally giving consent * unable to speak and read english or chinese

Keywords: randomised controlled trial decision aid heart failure